Skin conditions like dermatitis, psoriasis and eczema can have a big impact on your quality of sleep. Lifeloom bedding with DermaTherapy's innovative microfiber fabric doesn’t contain any of the abrasive fibers that are commonly found in cotton sheets. The result is skin-friendly bedding that increases comfort and reduces friction by 35%.
The Department of Dermatology, School of Medicine at Wake Forest University conducted an 8-week clinical trial involving patients with mild eczema and/or psoriasis. Compared to their current cotton bedding, participants saw:
"I LOVE these sheets! They have allowed me to get more rest at night. I've had psoriasis for many years and these sheets feel great against my skin. I am so thankful to finally find something that helps me sleep more comfortably. My skin does not tear against these sheets. My skin looks better and I get a good nights sleep!"
DermaTherapy® has FDA clearance as a Class I medical device for atopic dermatitis, eczema and psoriasis, and pressure sores. DermaTherapy® is the first and only bedding to achieve this distinction. Technical indications for use of DermaTherapy® include:
* Class I medical device for use by people in hospital, healthcare or home settings who are susceptible to or may have atopic dermatitis, the most common form of eczema. (Reg. K061242)
Lifeloom’s bedding uses DermaTherapy® fabric technology, which is woven from a strong, continuous-filament yarn that creates a consistently smooth, silk-like surface. Our fabrics are lint free and release almost no contaminating particles that can irritate the skin and infiltrate pores. Most importantly to those experiencing psoriasis and eczema, friction and skin abrasiveness are virtually eliminated while moisture is wicked away from the fabric.
Lifeloom's DermaTherapy® fabric technology has been tested many times for skin sensitivity as it may relate to concerns from those suffering with psoriasis and eczema. These tests included analyses of skin irritation, skin sensitization, and cytotoxicity. In all such testing, the fabric showed passing results, with no cytotoxicity or sensitivity for at-risk skin. The FDA reviewed test results and found them to pass standards for medical devices used in contact with the skin.
* Standard No. ISO 10993-5, “Biological Assessment of Medical Products, Part 5: Tests for Cytotoxicity – MEM Elution; Version 10993-5”, Standard Date 01/01/1999
* Standard No. ISO 10993-10, “Biological Evaluation of Medical Devices – Part 10: Irritation: Intracutaneous Reactivity; Version 10993-10:2002(E)”, Standard Date 01/01/2002
* Standard No. ISO 10993-10, “Biological Evaluation of Medical Devices – Part 10: Tests for Irritation and Sensitization – Maximum Sensitization
Test; Version10993-10:2002(E)”, Standard Date 01/01/2002
Lifeloom’s bedding is crafted from DermaTherapy® fabric technology, and is woven from a blend of polyester and nylon yarns.
Our FDA-cleared bedding is made in the United States.
The DermaTherapy® fabric technology is crafted from woven fibers with unique cross sections that create micro-channels. These micro-channels carry–or “wick”–moisture away from skin, keeping your skin fresh and pores clean.
Initial results are typically seen within 2-3 weeks.
All Lifeloom bedding made with DermaTherapy® fabric technology meet the strictest standards of quality as defined by our stringent ISO 9001 certification. You can expect to realize the mitigating benefits of our bedding within 2–3 weeks. Should you become dissatisfied with your purchase for any reason, Lifeloom will accept a return within 90 days of date-of-purchase. Customer is responsible for return shipping, and returns will be refunded in the original method of payment. It is recommended to use a tracking number when returning product.
All linens crafted using DermaTherapy® technology include a one-year warranty against manufacturer defects.
Department of Dermatology, School of Medicine, Wake
Forest Baptist Medical Center, Winston-Salem, North
Carolina, 2017.
Eleanor J. Kurtz, BSEE, Christopher B. Yelverton, MD, MBA, Fabian T. Camacho, MS, and Alan B. Fleisher Jr., MD. Department of Dermatology, Wake Forest University School of Medicine. Pediatric Dermatology, Vol. 25, No. 4, 439-443, 2008.